261 related articles for article (PubMed ID: 21489314)
1. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
[TBL] [Abstract][Full Text] [Related]
3. Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
Zhang H; Prado K; Zhang KX; Peek EM; Lee J; Wang X; Huang J; Li G; Pellegrini M; Chin AI
Clin Cancer Res; 2016 Nov; 22(21):5349-5361. PubMed ID: 27189164
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.
da Silva GN; de Castro Marcondes JP; de Camargo EA; da Silva Passos Júnior GA; Sakamoto-Hojo ET; Salvadori DM
Exp Biol Med (Maywood); 2010 Jul; 235(7):814-24. PubMed ID: 20558835
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
6. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
[TBL] [Abstract][Full Text] [Related]
7. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
8. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer.
Nordentoft I; Birkenkamp-Demtroder K; Agerbæk M; Theodorescu D; Ostenfeld MS; Hartmann A; Borre M; Ørntoft TF; Dyrskjøt L
BMC Med Genomics; 2012 Sep; 5():40. PubMed ID: 22954303
[TBL] [Abstract][Full Text] [Related]
9. β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.
Kallifatidis G; Smith DK; Morera DS; Gao J; Hennig MJ; Hoy JJ; Pearce RF; Dabke IR; Li J; Merseburger AS; Kuczyk MA; Lokeshwar VB; Lokeshwar BL
Mol Cancer Ther; 2019 Apr; 18(4):801-811. PubMed ID: 30787175
[TBL] [Abstract][Full Text] [Related]
10. No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
Camargo EA; da Silva GN; Gobette CP; Marcondes JP; Salvadori DM
Asian Pac J Cancer Prev; 2013; 14(10):5941-8. PubMed ID: 24289605
[TBL] [Abstract][Full Text] [Related]
11. Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.
da Silva GN; de Camargo EA; Salvadori DM
Mol Biol Rep; 2012 Dec; 39(12):10373-82. PubMed ID: 23053941
[TBL] [Abstract][Full Text] [Related]
12. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
13. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Ma Y; Yu WD; Trump DL; Johnson CS
Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
da Silva GN; Filoni LT; Salvadori MC; Salvadori DMF
Pathol Oncol Res; 2018 Apr; 24(2):407-417. PubMed ID: 28577130
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Matsumura N; Nakamura Y; Kohjimoto Y; Nishizawa S; Kikkawa K; Iba A; Kodama Y; Hara I
Int J Urol; 2017 Mar; 24(3):230-235. PubMed ID: 28066957
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine in the treatment of bladder cancer.
Ryan CW; Vogelzang NJ
Expert Opin Pharmacother; 2000 Mar; 1(3):547-53. PubMed ID: 11249537
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
[TBL] [Abstract][Full Text] [Related]
20. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
